Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO AND OXYCODONE CONTROLLED MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP

NCT00985621 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00985621
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00985621 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO AND OXYCODONE CONTROLLED MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
October 30, 2009
Completion date
February 4, 2011
Enrollment
614 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis